gefitinib has been researched along with cambinol in 1 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (cambinol) | Trials (cambinol) | Recent Studies (post-2010) (cambinol) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 53 | 0 | 42 |
| Protein | Taxonomy | gefitinib (IC50) | cambinol (IC50) |
|---|---|---|---|
| NAD-dependent protein deacetylase sirtuin-1 | Homo sapiens (human) | 8.85 | |
| Sphingomyelin phosphodiesterase 3 | Homo sapiens (human) | 5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bahra, M; Ehemann, V; Endris, V; Goeppert, B; Kamphues, C; Klauschen, F; Lorenz, K; Muckenhuber, A; Neuhaus, P; Sinn, B; Stenzinger, A; Warth, A; Weichert, W | 1 |
1 other study(ies) available for gefitinib and cambinol
| Article | Year |
|---|---|
High SIRT1 expression is a negative prognosticator in pancreatic ductal adenocarcinoma.
Topics: Aged; Aged, 80 and over; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Follow-Up Studies; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Naphthalenes; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Pancreatic Neoplasms; Prognosis; Pyrimidinones; Quinazolines; Sirtuin 1 | 2013 |